SAS Biotech Avenir represented by Florence Séjourné
Florence Séjourné is the chief executive officer of Da Volterra, a French biotech company that develops innovative products for the prevention and treatment of multi-resistant and life-threatening infections for which the medical need is increasing.
Prior to joining Da Volterra in 2008, Florence co-founded GENFIT with Jean-François Mouney and Bart Staels, and spent 11 years as a member of the Executive Board, and in particular held the position of Chief Operating Officer. She has been a member of the Supervisory Board and now Board of Directors of GENFIT since 2008, representing Biotech Avenir, the holding company of GENFIT managers and executives.
Furthermore, Florence has been active in contributing to various groups in Europe and in the United States focused on defining creative business models and incentives to face the economic issues of innovation in bacterial infections. She founded and is President of the BEAM Alliance, which represents 35 European biopharmaceutical companies involved in developing innovative products to tackle antimicrobial resistance. In addition, she is a board member, representative of SMEs, in the IRT BioAster, and member of the expert advisory board of GAMRIF, the Global AMR Innovation Fund launched by the UK government.
Florence holds a degree in biotechnology from MINES Paritech, in Paris, France and also holds a Master of Science in Pharmaceutical Sciences & Bioengineering from the University of Illinois, Chicago.